Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1974 2
1975 1
1986 2
1987 1
1989 1
1993 1
1997 1
1998 1
1999 2
2000 8
2001 2
2002 7
2003 11
2004 5
2005 8
2006 1
2007 8
2008 11
2009 4
2010 2
2011 5
2012 5
2013 6
2014 5
2015 6
2016 6
2017 10
2018 8
2019 17
2020 6
2021 11
2022 17
2023 7
2024 6

Text availability

Article attribute

Article type

Publication date

Search Results

177 results

Results by year

Filters applied: . Clear all
Page 1
Hypertriglyceridemia.
Chait A. Chait A. Endocrinol Metab Clin North Am. 2022 Sep;51(3):539-555. doi: 10.1016/j.ecl.2022.02.010. Epub 2022 Jul 4. Endocrinol Metab Clin North Am. 2022. PMID: 35963627 Review.
Although fibrates lower triglyceride levels, their role in CVD prevention remains unclear. Familial partial lipodystrophy is another relatively rare cause, although its true incidence is unknown....
Although fibrates lower triglyceride levels, their role in CVD prevention remains unclear. Familial partial lipodystrophy is a …
The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline.
Brown RJ, Araujo-Vilar D, Cheung PT, Dunger D, Garg A, Jack M, Mungai L, Oral EA, Patni N, Rother KI, von Schnurbein J, Sorkina E, Stanley T, Vigouroux C, Wabitsch M, Williams R, Yorifuji T. Brown RJ, et al. J Clin Endocrinol Metab. 2016 Dec;101(12):4500-4511. doi: 10.1210/jc.2016-2466. Epub 2016 Oct 6. J Clin Endocrinol Metab. 2016. PMID: 27710244 Free PMC article. Review.
Metreleptin therapy is effective for metabolic complications in hypoleptinemic patients with generalized lipodystrophy and selected patients with partial lipodystrophy. Other treatments not specific for lipodystrophy may be helpful as well (eg, metformin for diabete …
Metreleptin therapy is effective for metabolic complications in hypoleptinemic patients with generalized lipodystrophy and selected patients …
A Comprehensive Update on the Chylomicronemia Syndrome.
Goldberg RB, Chait A. Goldberg RB, et al. Front Endocrinol (Lausanne). 2020 Oct 23;11:593931. doi: 10.3389/fendo.2020.593931. eCollection 2020. Front Endocrinol (Lausanne). 2020. PMID: 33193106 Free PMC article. Review.
A third uncommon cause of the chylomicronemia syndrome is familial forms of partial lipodystrophy. Development of pancreatitis is the most feared complication of the chylomicronemia syndrome, but the risk of cardiovascular disease as well as non-alcoholic steatohepa …
A third uncommon cause of the chylomicronemia syndrome is familial forms of partial lipodystrophy. Development of pancreatitis …
Lamins and metabolism.
Charar C, Gruenbaum Y. Charar C, et al. Clin Sci (Lond). 2017 Jan 1;131(2):105-111. doi: 10.1042/CS20160488. Clin Sci (Lond). 2017. PMID: 27974395 Review.
Most of these diseases are autosomal dominant and can be roughly divided into four major groups: muscle diseases, peripheral neuronal diseases, accelerated aging disorders and metabolic diseases including Dunnigan type familial partial lipodystrophy (FLPD), acquired …
Most of these diseases are autosomal dominant and can be roughly divided into four major groups: muscle diseases, peripheral neuronal diseas …
Advances in the care of lipodystrophies.
Shamsudeen I, Hegele RA. Shamsudeen I, et al. Curr Opin Endocrinol Diabetes Obes. 2022 Apr 1;29(2):152-160. doi: 10.1097/MED.0000000000000695. Curr Opin Endocrinol Diabetes Obes. 2022. PMID: 34839327 Review.
This review summarizes the recent advances in the treatment of lipodystrophies, with a particular focus on the treatment of hypertriglyceridemia in familial partial lipodystrophy (FPLD). RECENT FINDINGS: Treatment of dyslipidemia in FPLD requires management of secon …
This review summarizes the recent advances in the treatment of lipodystrophies, with a particular focus on the treatment of hypertriglycerid …
Lipodystrophy for the Diabetologist-What to Look For.
Patni N, Garg A. Patni N, et al. Curr Diab Rep. 2022 Sep;22(9):461-470. doi: 10.1007/s11892-022-01485-w. Epub 2022 Jul 11. Curr Diab Rep. 2022. PMID: 35821558 Free PMC article. Review.
RECENT FINDINGS: The four major subtypes are autosomal recessive, congenital generalized lipodystrophy (CGL); acquired generalized lipodystrophy (AGL), mostly an autoimmune disorder; autosomal dominant or recessive familial partial lipodystrophy (FPLD); and acquired …
RECENT FINDINGS: The four major subtypes are autosomal recessive, congenital generalized lipodystrophy (CGL); acquired generalized lipodystr …
Familial partial lipodystrophy syndromes.
Fernández-Pombo A, Sánchez-Iglesias S, Cobelo-Gómez S, Hermida-Ameijeiras Á, Araújo-Vilar D. Fernández-Pombo A, et al. Presse Med. 2021 Nov;50(3):104071. doi: 10.1016/j.lpm.2021.104071. Epub 2021 Oct 2. Presse Med. 2021. PMID: 34610417 Review.
Lipodystrophies are a heterogeneous group of rare conditions characterised by the loss of adipose tissue. The most common forms are the familial partial lipodystrophy (FPLD) syndromes, which include a set of disorders, usually autosomal dominant, due to different pa …
Lipodystrophies are a heterogeneous group of rare conditions characterised by the loss of adipose tissue. The most common forms are the fami …
Treatment Options for Lipodystrophy in Children.
Mainieri F, Tagi VM, Chiarelli F. Mainieri F, et al. Front Endocrinol (Lausanne). 2022 May 4;13:879979. doi: 10.3389/fendo.2022.879979. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 35600578 Free PMC article. Review.
Recently, metreleptin was approved by Food and Drug Administration (FDA) for the treatment of generalized lipodystrophy and by European Medicines Agency (EMA) for the treatment of both generalized and partial lipodystrophy. However, further research is being conduct …
Recently, metreleptin was approved by Food and Drug Administration (FDA) for the treatment of generalized lipodystrophy and by European Medi …
Lipoatrophy revisited.
Reitman ML, Arioglu E, Gavrilova O, Taylor SI. Reitman ML, et al. Trends Endocrinol Metab. 2000 Dec;11(10):410-6. doi: 10.1016/s1043-2760(00)00309-x. Trends Endocrinol Metab. 2000. PMID: 11091118 Review.
Causative mutations have been identified in patients for one form of partial lipoatrophy--Dunnigan-type familial partial lipodystrophy. Experiments using lipoatrophic mice demonstrate that the diabetes results from the lack of fat and that leptin deficiency is a con …
Causative mutations have been identified in patients for one form of partial lipoatrophy--Dunnigan-type familial partial lipodystr …
An overview of lipodystrophy and the role of the complement system.
Corvillo F, Akinci B. Corvillo F, et al. Mol Immunol. 2019 Aug;112:223-232. doi: 10.1016/j.molimm.2019.05.011. Epub 2019 Jun 6. Mol Immunol. 2019. PMID: 31177059 Review.
Complement over-activation has been reported in most of the patients with acquired partial lipodystrophy (also called Barraquer-Simons Syndrome) and in some cases of the generalized variety of the disease (Lawrence Syndrome). ...
Complement over-activation has been reported in most of the patients with acquired partial lipodystrophy (also called Barraque …
177 results